Monofunctional Platinum(II) Anticancer Agents
Platinum-based anticancer drugs represented by cisplatin play important roles in the treatment of various solid tumors. However, their applications are largely compromised by drug resistance and side effects. Much effort has been made to circumvent the drug resistance and general toxicity of these d...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/14/2/133 |
| _version_ | 1797413231294152704 |
|---|---|
| author | Suxing Jin Yan Guo Zijian Guo Xiaoyong Wang |
| author_facet | Suxing Jin Yan Guo Zijian Guo Xiaoyong Wang |
| author_sort | Suxing Jin |
| collection | DOAJ |
| description | Platinum-based anticancer drugs represented by cisplatin play important roles in the treatment of various solid tumors. However, their applications are largely compromised by drug resistance and side effects. Much effort has been made to circumvent the drug resistance and general toxicity of these drugs. Among multifarious designs, monofunctional platinum(II) complexes with a general formula of [Pt(3A)Cl]<sup>+</sup> (A: Ammonia or amine) stand out as a class of “non-traditional” anticancer agents hopeful to overcome the defects of current platinum drugs. This review aims to summarize the development of monofunctional platinum(II) complexes in recent years. They are classified into four categories: fluorescent complexes, photoactive complexes, targeted complexes, and miscellaneous complexes. The intention behind the designs is either to visualize the cellular distribution, or to reduce the side effects, or to improve the tumor selectivity, or inhibit the cancer cells through non-DNA targets. The information provided by this review may inspire researchers to conceive more innovative complexes with potent efficacy to shake off the drawbacks of platinum anticancer drugs. |
| first_indexed | 2024-03-09T05:14:40Z |
| format | Article |
| id | doaj.art-0f43b455040d47c3b6f3bb729a7e2115 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T05:14:40Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-0f43b455040d47c3b6f3bb729a7e21152023-12-03T12:46:10ZengMDPI AGPharmaceuticals1424-82472021-02-0114213310.3390/ph14020133Monofunctional Platinum(II) Anticancer AgentsSuxing Jin0Yan Guo1Zijian Guo2Xiaoyong Wang3State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, ChinaState Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, ChinaState Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, ChinaState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023, ChinaPlatinum-based anticancer drugs represented by cisplatin play important roles in the treatment of various solid tumors. However, their applications are largely compromised by drug resistance and side effects. Much effort has been made to circumvent the drug resistance and general toxicity of these drugs. Among multifarious designs, monofunctional platinum(II) complexes with a general formula of [Pt(3A)Cl]<sup>+</sup> (A: Ammonia or amine) stand out as a class of “non-traditional” anticancer agents hopeful to overcome the defects of current platinum drugs. This review aims to summarize the development of monofunctional platinum(II) complexes in recent years. They are classified into four categories: fluorescent complexes, photoactive complexes, targeted complexes, and miscellaneous complexes. The intention behind the designs is either to visualize the cellular distribution, or to reduce the side effects, or to improve the tumor selectivity, or inhibit the cancer cells through non-DNA targets. The information provided by this review may inspire researchers to conceive more innovative complexes with potent efficacy to shake off the drawbacks of platinum anticancer drugs.https://www.mdpi.com/1424-8247/14/2/133anticancer drugdrug designmetal-based drugmonofunctional platinum complex |
| spellingShingle | Suxing Jin Yan Guo Zijian Guo Xiaoyong Wang Monofunctional Platinum(II) Anticancer Agents Pharmaceuticals anticancer drug drug design metal-based drug monofunctional platinum complex |
| title | Monofunctional Platinum(II) Anticancer Agents |
| title_full | Monofunctional Platinum(II) Anticancer Agents |
| title_fullStr | Monofunctional Platinum(II) Anticancer Agents |
| title_full_unstemmed | Monofunctional Platinum(II) Anticancer Agents |
| title_short | Monofunctional Platinum(II) Anticancer Agents |
| title_sort | monofunctional platinum ii anticancer agents |
| topic | anticancer drug drug design metal-based drug monofunctional platinum complex |
| url | https://www.mdpi.com/1424-8247/14/2/133 |
| work_keys_str_mv | AT suxingjin monofunctionalplatinumiianticanceragents AT yanguo monofunctionalplatinumiianticanceragents AT zijianguo monofunctionalplatinumiianticanceragents AT xiaoyongwang monofunctionalplatinumiianticanceragents |